Repligen | RGEN - Current Liabilities


Repligen reported $126.21M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Agilent USD 2.27B 35M Mar/2026
Align Technology USD 1.91B 14.16M Mar/2026
Bio Techne USD 153.28M 12.85M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Bruker USD 1.36B 75.9M Mar/2026
Charles River Laboratories USD 1.09B 26.61M Mar/2026
Danaher USD 7.46B 653M Mar/2026
Dentsply International USD 1.21B 136M Mar/2026
General Electric Aerospace USD 40.03B 1.05B Mar/2026
Henry Schein USD 3.3B 69M Mar/2026
Illumina USD 1.57B 19M Mar/2026
IQVIA Holdings USD 8.33B 9M Mar/2026
Mettler Toledo International USD 1.11B 89.76M Mar/2026
Myriad Genetics USD 130.2M 3.6M Mar/2026
OraSure Technologies USD 44.08M 4.29M Mar/2026
Pacific Biosciences Of California USD 65.36M 7.48M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Repligen USD 126.21M 9.62M Mar/2026
Revvity USD 1.24B 92.6M Mar/2026
Standard Biotools USD 42.2M 66.1M Mar/2026
Thermo Fisher Scientific USD 14.62B 568M Mar/2026
Waters USD 1.24B 11.8M Dec/2025
West Pharmaceutical Services USD 674M 19.1M Mar/2026